序号 |
标题 |
次数 |
作者 |
发布时间 |
75151 |
聚DOTA新型树枝状分子(PDOTA) |
95 |
h |
2024-12-18 |
75152 |
Anti-EGFR (cetuximab)-EDC/NHS-methotrexate |
144 |
kx |
2024-12-18 |
75153 |
CAS号为646502-53-6的MC-Val-Cit-PAB-MMAE |
132 |
WYQ |
2024-12-18 |
75154 |
介孔硅纳米粒子(MSNs) |
178 |
h |
2024-12-18 |
75155 |
DO3A-Ether-Rhein 10-{[6-(1,8-二羟基蒽醌-3-甲酰氨基)乙氧基乙基]氨基}羰酰甲基-1,4,7,10-四氮杂环十二烷-1,4,7-三乙酸 |
90 |
h |
2024-12-18 |
75156 |
MC-Val-Cit-PAB-MMAF(或简写为Vc-MMAF) |
102 |
WYQ |
2024-12-18 |
75157 |
Anti-CD33 (h2H12ec)-Mc-VC-SGD-1882, ADC试剂 |
107 |
kx |
2024-12-18 |
75158 |
FITC-cNGR 绿色荧光素FITC标记cNGR环状 |
93 |
h |
2024-12-18 |
75159 |
Azide-PEG3-Val-Cit-PAB-MMAF,叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
81 |
WYQ |
2024-12-18 |
75160 |
cas:2454675-51-3,t-butyl-C18-D-Glu-OtBu,ADC定制 |
95 |
wyh |
2024-12-18 |
75161 |
包裹瑞喹莫德的PS脂质体(PS-R848),包裹R848的PS仿生脂质体 |
191 |
axc |
2024-12-18 |
75162 |
MC-Val-Cit-Doxorubicin(CAS号:159857-70-2) |
82 |
WYQ |
2024-12-18 |
75163 |
Anti-CD22 (clone G5/44)-AcBut-CalichDMH,ADC定制 |
79 |
kx |
2024-12-18 |
75164 |
cas:870487-07-3,Fmoc-Lys(Boc)-PAB-PNP,ADC定制 |
82 |
wyh |
2024-12-18 |
75165 |
cas:2055042-67-4,Azido-PEG4-Ala-Ala-Asn(Trt)-PAB,ADC定制 |
106 |
wyh |
2024-12-18 |
75166 |
蜚蠊提取物长效脂质体,CE-Lip,靶向脂质体定制服务 |
124 |
axc |
2024-12-18 |
75167 |
cas:150114-97-9,Fmoc-Val-Ala-OH ,Fmoc-L-缬氨酰-L-丙氨酸 |
89 |
kx |
2024-12-18 |
75168 |
Biotin-PEG11-Gly-Gly-Gly-Amine,生物素-PEG11-甘氨酸三肽-胺,ADC定制 |
66 |
wyh |
2024-12-18 |
75169 |
Azido-PEG4-Val-Ala-PAB-PNP,由叠氮基团(-N3)、PEG4、Val、Ala、PAB和PNP组成 |
122 |
WYQ |
2024-12-18 |
75170 |
三分枝脂质体配体,3RGD-Chol,提供荧光脂质体定制服务 |
108 |
axc |
2024-12-18 |
75171 |
cas:1343476-44-7,Val-Ala-PAB-OH , ADC试剂 |
79 |
kx |
2024-12-18 |
75172 |
cas:28320-73-2,Boc-Gly-Gly-Gly-OH,ADC定制 |
114 |
wyh |
2024-12-18 |
75173 |
双分枝脂质体配体,2RGD-Chol,脂质体纳米载体定制服务 |
100 |
axc |
2024-12-18 |
75174 |
MC-Val-Cit-PAB-Gly, ADC试剂 |
83 |
kx |
2024-12-18 |
75175 |
DBCO-PEG4-Val-Ala-PAB,由DBCO、PEG4、Val、Ala和PAB组成 |
83 |
WYQ |
2024-12-18 |
75176 |
DBCO-PEG4-Val-Ala-PAB-PNP |
73 |
WYQ |
2024-12-18 |
75177 |
1343407-91-9,Alloc-Val-Ala-PAB-OH,ADC定制 |
111 |
wyh |
2024-12-18 |
75178 |
cas:870487-09-5,Boc-Val-Cit-PAB |
92 |
kx |
2024-12-18 |
75179 |
cas:2353409-69-3,Mal-PEG8-Val-Cit-PAB-MMAE,ADC定制 |
134 |
wyh |
2024-12-18 |
75180 |
cas:159858-33-0,Val-Cit ,L-缬氨酰基-L-瓜氨酸 |
70 |
kx |
2024-12-18 |
75181 |
单分枝脂质体配体,1RGD-Chol,多功能载药脂质体定制服务 |
69 |
axc |
2024-12-18 |
75182 |
1350456-56-2,Fmoc-Val-Cit-PAB-MMAE,ADC定制 |
125 |
wyh |
2024-12-18 |
75183 |
H-Val-Ala-OH(缬氨酰-丙氨酸),CAS号:27493-61-4 |
77 |
WYQ |
2024-12-18 |
75184 |
cas:1869126-64-6,Azido-PEG4-Val-Cit-PAB-MMAE,ADC定制 |
72 |
wyh |
2024-12-18 |
75185 |
cas:890409-85-5 , Py-ds-dmBut-OSu |
101 |
kx |
2024-12-18 |
75186 |
Val-Ala-PAB-OH,一种用于合成抗体药物偶联物(ADCs)的化学化合物 |
104 |
WYQ |
2024-12-18 |
75187 |
重组E.coli细胞表达类弹性蛋白多肽-超氧化物歧化酶融合蛋白脂质体,ELP-SOD |
172 |
axc |
2024-12-18 |
75188 |
cas:1222490-34-7 , PBD-dimer PBD二聚体 |
78 |
kx |
2024-12-18 |
75189 |
Azido-PEG4-Val-Ala-PAB,分子式:C29H48N8O9 |
105 |
WYQ |
2024-12-18 |
75190 |
cas:1394238-91-5,Fmoc-Val-Ala-PAB,ADC定制 |
80 |
wyh |
2024-12-18 |
75191 |
多柔比星脂质体,多功能载药脂质体定制服务 |
113 |
axc |
2024-12-18 |
75192 |
cas:1869126-64-6 , Azido-PEG4-Val-Cit-PAB-MMAE,叠氮-四聚乙二醇-VAL-CIT-PAB-MMAE |
77 |
kx |
2024-12-18 |
75193 |
Ald-CH2-PEG5-t-butyl ester,cas:1446282-23-0 |
101 |
zyl |
2024-12-18 |
75194 |
DOTA-anti-CITED1-PNA DOTA-anti-转化激活因子-肽核酸 |
67 |
h |
2024-12-18 |
75195 |
Mal-Val-Ala-PAB,一种可降解的ADC连接子 |
125 |
|
2024-12-18 |